Atipamezole

DB11481InvestigationalVet approvedSmall molecule

Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. It has also been undergone research as a potential anti-Parkinsonian...

Mechanism: Pharmacologically active on Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, and Alpha-2B adrenergic receptor
Curator reviewed
Primary indication: For the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.Curator reviewed
Formula / weight: C₁₄H₁₆N₂ · 212.296 g/mol (avg)
Code names: MPV-1248

Resolves to

Compound

UNII03N9U5JAF6CAS104054-27-5ChEMBLCHEMBL353972KEGGD03002

Clinical / RWD

RxNorm18475

Structure

InChIKeyHSWPZIDYAHLZDD-UHFFFAOYSA-NSMILESCCC1(CC2=CC=CC=C2C1)C1=CN=CN1

Targets

P08913ADRA2AP18825ADRA2CP18089ADRA2B

What you can answer from here — as of August 30, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

551Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atipamezole, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In